Podcasts about Market access

Tyler O'Malley is the Vice President of Clinical Affairs, Bioinformatics, and Market Access at Exagen, Inc. Tyler shares his journey in the MedTech industry and discusses Exagen's innovative approaches to autoimmune testing solutions, including cutting-edge diagnostics for lupus and other diseases. With over a decade of experience, Tyler provides insights into the challenges and breakthroughs in the field, highlighting the significance of early diagnosis and personalized treatment, while also discussing the challenges and opportunities in effective leadership during different stages of company growth.   Guest links: https://exagen.com/ Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 066 - Tyler O'Malley [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and I am so excited to introduce you to my guest today, Tyler O'Malley. Tyler serves as Associate VP of Clinical Affairs and Market Access at Exagen, Inc., a leader in autoimmune testing solutions. In his role, he oversees clinical trials, bioinformatics, and medical policy development for Exagen's current diagnostic portfolio and pipeline of proprietary solutions. With more than a decade of experience, O'Malley has contributed to more than a dozen clinical trials focusing on clinical validity and utility evidence for autoimmune diagnostics. His expertise is widely recognized with numerous publications in esteemed peer reviewed journals, and notably, he's the first author of one of the largest clinical utility studies in lupus diagnostics. O'Malley graduated from Georgia Gwinnett College with a Bachelor of Science in biology, concentrating in biochemistry. His 11 year career in research and development and medical affairs encompass medical science, education, assay development, and clinical research coordination. Well, welcome to the show, Tyler. I'm so excited to have you here today. [00:02:01] Tyler O'Malley: Thanks, glad to be here. [00:02:02] Lindsey Dinneen: Yeah, absolutely. Well, I would love just starting off by telling us a little bit about yourself, your background, and what led you to MedTech. [00:02:11] Tyler O'Malley: Sure. So, I'm the Vice President of Clinical Affairs, Bioinformatics, and Market Access at Exagen. We're a specialty diagnostics company focused on autoimmune rheumatic diseases. So we develop proprietary testing technology for conditions like lupus, rheumatoid arthritis, Sjogren's disease, as well as many others. And yeah, our focus is trying to find solutions for patients who are dealing with what are many times challenging chronic diseases that can present themselves in very mysterious ways oftentimes. And so, these are challenges that patients have that have, for the most part, gone unsolved for many decades, and so there's a lot of opportunity out there. In terms of, myself, my background, I've been with Exagen for the past 11 and a half years. So I've been doing this for a while now, and I've worked in a couple of different areas within the organization, doing work within the lab assay development, as well as outside the lab doing clinical research, statistical analysis, which led to the bioinformatics role. And then as well as doing some work trying to align our clinical evidence with medical policy for our tests which is the market access role. So, a little bit of everything, but there are some through lines that I assure you do make some sense if you really think about it. [00:03:33] Lindsey Dinneen: Excellent. Excellent. Well, thank you for sharing a little bit about that. There's so much to dive into, but going back a little bit in your story, when you were thinking about careers-- you're a eager high school student ready to embrace college, and you're ready for the next step --is this something that you could have imagined yourself doing or has this always been a passion of yours? Or is this something you kind of found yourself in? [00:03:57] Tyler O'Malley: Not at all. So, no I, so I will say I've always been interested in autoimmunity. So that's always been something that has always piqued my interest, whether I was in high school or college. And so I guess in that sense, it's not a surprise. But the laboratory diagnostics component of it was not something that was on my radar when I was in high school or college. And I guess the journey to Exagen was, after graduating from high school, went and got a bachelor's degree in biology with a biochemistry focus. So, that's sort of my background there. And while I was getting the degree and focusing on biochemistry, I had the opportunity through a resource scholarship at Georgia Tech to work in a graduate lab, which was a really interesting experience where, you know, for a little over a year I had the opportunity to work alongside PhD candidates, postdocs, on a research project that was partially funded and get the experience and understand what it's like to work towards a PhD and what it would look like to kind of go down that path of graduate level research. And I think it had the opposite effect that it was intended to have in that it kind of showed me I didn't want to do that. So, I think in a lot of ways I was happy I had that experience 'cause it showed me before I went down that path that it was something I didn't wanna do. Nothing against it, I guess I wanted to do something that maybe had more of a translational impact, a little bit closer to the patient. And so, finished my degree, and at the time I was living in Georgia, so I finished my degree in Georgia, left and moved out to California, and ended up at Exagen by pure chance through a recruiter. And that was back in 2014, and basically just joined Exagen at the time when it was a smaller company, and grew with the company, and was fortunate enough to have the ability to learn a lot of different functions within the company as it grew, and there were a lot of different things that needed to be done a as the company was growing. And so it, it's been kind of a, an interesting ride since then. [00:06:08] Lindsey Dinneen: Yeah, absolutely. And of course all of those different experiences, I'm sure, have woven their way in, like you said. Sometimes you have to kind of look for that line, but there is one that's, apparent when you look back. So, can you talk a little bit more about the company, what it does, especially in regards to its testing technology, and I'd love to hear about some of the innovation that's just coming out of this incredible organization you're a part of. [00:06:35] Tyler O'Malley: Sure. So our our testing, again, primarily focuses on addressing unmet needs in patients who have autoimmune connective tissue diseases. And specifically we have some proprietary technology around biomarkers that help diagnose systemic lupus. And lupus is kind of the prototypical autoimmune disease in that it can manifest in just about any different way. It can show up in your skin, your heart, your lungs, your kidneys, just about any way you can imagine, and sometimes in multiple different ways. And so in that way, it can be challenging to diagnose 'cause it can look like so many different things. And much of the testing that is used for lupus or has been used traditionally is very antiquated. Antibody tests that were developed many decades ago that have been refined to some extent over the years, but for the most part are not overly sophisticated. So, what Exagen has done over the past 15 or so years is brought forward some technology, that was originally licensed from University of Pittsburgh, looking at measuring a form of the complement system, which is a part of our immune system. It's a very ancient form of our immune system. It's a collection of proteins that come together to help fight off pathogens and help clear debris to keep our our immune system healthy. And what we're able to do is measure essentially the buildup of a complement fragment that builds up on your red blood cells and on your B lymphocytes. And what this does is it gives us a unique ability to detect lupus that's much more sensitive than the conventional means. And what that means, when I say sensitivity, is that it's able to pick up more lupus patients than the conventional testing. So, one way of thinking about this is like, if you have a hundred patients in a room that all have lupus, right? Because they've been assessed by a doctor, they've been clinically diagnosed, and you were to test them, and say your conventional test is 50% sensitive, meaning half of the room would test positive on this test and the other half would test negative. This test that we're talking about here, it would pick up two thirds of the room, right, as opposed to conventional testing, which would pick up fewer patients. So, that's the kind of technology that we're trying to develop here, which is trying to be more inclusive, pick up more patients sooner, give better insights to physicians to combine with their clinical assessments such that patients can get earlier treatments and hopefully stave off some of the more kind of disastrous outcomes of the disease that come with not getting treated soon enough and not getting treated appropriately for their symptoms. [00:09:31] Lindsey Dinneen: Yeah, of course. That's incredibly important and I'm so glad that the company is working to create those solutions, like you said, because previous methods while maybe somewhat useful, are more antiquated at this point. And so it's really important to have these new strides in innovation. So as you're dealing with all of this, I'm sure that there are stories that have come up about real people having impacted lives because of the technology that your company is bringing. Do you have any examples that you could share with us about that? [00:10:05] Tyler O'Malley: Sure. Yeah, there's been a number of individuals that we've had the fortune of meeting over the years. And they come and share the story with our team. We like to bring folks in with, for example, when we bring on new sales team members, we try to bring on a patient just to be able to share their story. So, recently we had an individual, who is connected to someone who works in our organization-- again, just pure chance-- who happened to have a very unique story. So first of all, lupus, for those who don't know, is a condition that primarily affects women. Lupus is a disease that affects women at a ratio of nine to one, nine to one female to male or so, in other words, around 90% of lupus patients are women. But that's not to say that it isn't an issue for that subset of of men that do develop lupus. And in fact, the disease tends to be more severe in that 10% of lupus patients that are men. So this individual who we've had the chance to meet and hear his story, really interesting because he's-- you would never know if you met this guy-- because he's a CrossFit guy. He is probably the healthiest guy you can imagine looking at him. But he went a harrowing journey to get to his diagnosis. And it all started with, relatively -- well, I don't wanna downplay it-- but let's call it "less severe symptoms" like alopecia and rashes, things like this that sort of make you think, "Well, gee, that's strange," or "I wonder what that is all about." And then leading up to much, much more severe symptoms like severe edema and pericarditis that was ultimately life threatening. And ultimately, he was able to get the right testing and get to the right doctors, but it was not a short journey from the time that these symptoms initially presented themselves to the time where he was able to get to the test and to get to the right diagnosis and onto the right treatment. The good news is, he's in a much better place now after finding out what's causing his symptoms and getting to a treatment management plan that works for him and he's even back to getting to an exercise routine that works for him. It's maybe not exactly the same as what it was before, but I mean, that's the thing. Now, you can lead a relatively normal life with lupus. It wasn't that long ago, call it several decades ago, where the mortality rate for lupus was as high as 50% in the first year after diagnosis. Treatment advances have greatly improved that and have changed the lives of people who live with Lupus now, but it used to be a very severe diagnosis. It still is, but it's very manageable now. [00:12:54] Lindsey Dinneen: Wow. Yeah. And so catching it and having that answer to, like you said, really difficult health journey where you're just not sure what's going on. And I really appreciate you talking a little bit about how Lupus looks different and manifests itself differently in different circumstances so it can be difficult to initially diagnose. So I love the fact that the company is focusing on things like that, when caught early can maybe make a huge difference in somebody's life like the gentleman you mentioned. Thank you for sharing about that. So now your own career has been really interesting in that you have gotten to do a lot of different things within the company and learn so much. Now as you've continued to grow with the company, you've, I'm sure, developed a lot of different leadership skills along the way, and I'm curious what it's been like in that sense of your journey to embrace leadership and how do you go about it? What have you found works really well, and maybe what advice would you have for somebody who's a little bit earlier in their career? [00:13:58] Tyler O'Malley: Yeah. Really interesting question. And I, I guess, my experience was, I came into an organization that was, I think at the time, maybe in the entire company was maybe 60, 70 people. So, as you can imagine, it was a very flat organization. I reported directly to the Chief Scientific Officer when I first joined the organization as a relatively low level R&D employee. So that afforded me, I think, a unique opportunity because I was often involved with project planning and discussions that I don't know that you get that opportunity in different types of corporate settings. And I think what has proven very useful in terms of my development, and as I look back and reflect on kind of what's led me here is, I can just recall, so, so many times, especially early on in, in a startup-- which can sometimes be chaotic and there's a lot of moving parts and things are moving fast-- there would be times where I would be in meetings where I wasn't necessarily expected to do very much, I think, or contribute much. And I would just sort of observe, right? And I think there's so much you can learn through not just listening to the conversation, but the body language of the people around the table. The way that people present, the way that people take criticism, the way that they respond. It was almost like a, it was a lesson every day just watching that. And I think where I thrived and maybe added value at times was realizing when people were talking past one another and just, at times, trying to find a way to come into that and say, "Well, right, but did you consider maybe what this person was trying to communicate here?" And, you can't always resolve those sorts of situations, but sometimes you can. And that's really valuable when you can help two individuals get past an impasse like that. So, and I think it helps you build credibility doing that too, being a bridge builder in that sense. And, and I think, that was something I don't know-- whether intuitively or purely by accident, I don't know-- I figured out over time was that, maybe as a young person in your career, sometimes it can be easy to get caught up on sort of the X's and O's of your job, whatever it is that you're doing-- if you're a computer programmer, you're doing bioinformatics or whatever the case may be-- you can get really caught up in the technical skills that you're trying to hone and develop. But there's so many soft skills that you have to build as well at the same time. And there's the relationships that you build, as well, that you don't know when you're gonna need them or when they'll pay off. But things change at organizations and you're glad when you have those relationships when it comes time to need them. [00:16:51] Lindsey Dinneen: Yeah. Absolutely. Yeah. I love your discussion on the idea of being a bridge builder, because I've been thinking a lot about that recently where there's so much unintentional missed communication, just literally just passing by where, one person is saying something, the other person's saying something, and as an outsider, you're able to have a little bit of a distance to go, "Oh, you're kind of saying the same thing, but I'm not sure that you guys realize that, and here's how." Yeah, that translating is a really important skillset and a fun one when you can nail it down. So as you look towards the future of your own career and the company's trajectory, what are some things that you're looking forward to? [00:17:35] Tyler O'Malley: Well, we obviously have a number of exciting pipeline initiatives that bring a lot of energy to me as I think about what we're trying to do going forward. I'm excited about where the company is headed in terms of its trajectory. I've described my time at the company as, even though I've been at the same company for 11 and a half years or so, I really feel like I've worked for three different companies in that time, in that, there was a period of time that was a startup up until the point the company went public. And then there was this time from when the company was public, where we raised a lot of money, there were a lot of expectations and didn't exactly kind of work out exactly as we had hoped. And then there was a leadership change. And now we're sort of in this third phase now where the arrow's pointing up and we have realigned our strategy here and we found a way to be sustainable and to be able to continue to build on something where hopefully we can continue to find interesting technology that's out there. We have an ongoing partnership with, as an example, Johns Hopkins University to try to develop a test to help address lupus nephritis. So this is a particular form of organ manifestation of lupus. It's one of the more common manifestations of lupus, and one of the more devastating forms of lupus, in that almost 50% of lupus patients will have kidney involvement at some point in their disease. And as much as 10 to 20% of patients who do have lupus nephritis will go on to unfortunately develop end stage kidney disease and require dialysis or kidney transplant. So it's obviously life altering and can be, very impactful to individuals. So, to be able to work on something like that and be able to potentially alter the trajectory of someone's life in that way is pretty cool to think about. And, not everyone gets to do that. I mean, it's not that other jobs aren't meaningful, it's just not everyone gets the opportunity to do that kind of thing. And if you can also find joy in what you're doing in your job. I think that's also great too. I mean, it's really cliche, the things people say, and so I won't do it. The whole, like, " If you like what you do, you never work." Believe me, it's work. I do feel like I'm working sometimes, for sure, but I can't complain. I do, for the most part, have fun with what I'm doing. I'm fortunate enough, I have a great team of people, well-- three teams of people-- that I really enjoy working with, and being able to work with people and see them grow and develop and be a part of that is also super rewarding as well too. So, yeah, I'm just, I'm having a lot of fun. [00:20:26] Lindsey Dinneen: Yeah. Excellent. Wonderful. Well, gosh, I'm gonna pivot the conversation just for fun a little bit. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. Now, this could be within your industry, but it doesn't have to be. What would you choose to teach? [00:20:45] Tyler O'Malley: I think that-- maybe this is kind of fun, probably not-- but I think that ,I don't know why, and it's funny because it's-- I don't even know if this qualifies because I don't even know how I would teach it-- but I think I'm fairly good at guesstimating numbers and it's really useful in that it helps in a lot of different situations to be able to shortcut math. And to be clear, it's not that I'm doing long division in my head or anything like that, but it's, if you can kind of shortcut and get the approximate number, it can be really useful. And it's a nice kind of party trick too kind of thing. Again, I don't know how I would teach it 'cause it's sort of like it's up here, and I don't know how I would externalize that, but yeah, that's something I feel like would be kind of cool to figure out how I could teach that. [00:21:35] Lindsey Dinneen: Absolutely. Yeah. It's a superpower. So it would be very cool to try to then-- you've got this innate ability-- so then to try to break it down into how does somebody else develop the skill sets that you just sort of possess, and go from there. That would be really entertaining. I love it. Great answer. Okay. And then the next question is, how do you wish to be remembered after you leave this world? [00:21:59] Tyler O'Malley: Yeah. Well, that's a deep question. I think that the most meaningful impact that you can have is the impression you leave on the people that you interacted with, right? And I think, for me, I would just hope that the people that I've had the chance to spend time with-- obviously family, friends, people I worked with, people who worked on my teams-- I would just hope that as they would reflect on the time that we had together, that it would be a memory that was time well spent and that hopefully there are some good shared experiences that we had and that hopefully I left something that was meaningful. But as it relates to the work that we're doing, I hope that the impact that we're having-- some of it has a longer reach than even what we can see today, 'cause I think, truly being selfless is trying to build things that you'll never realize the benefit of: planting trees that you'll never sit under yourself. It's for someone else down the line in the future. [00:23:14] Lindsey Dinneen: Yeah. Yeah. I love thinking about it in those terms too: being willing to do your bits of good and let them go out into the world and not necessarily know the ripple effects and still use that as a worthwhile use of your time. I love that. And then final question, what is one thing that makes you smile every time you see or think about it? [00:23:39] Tyler O'Malley: Yeah, I think the easy answer is probably my kids. So I have two kids, and that's kind of the reprieve from the work life and kind of focusing on all this important stuff that we're trying to do here at work, but being able to kind of break away from that and focus on building them up and watching them grow and develop and become their own person is really cool. It's obviously a unique experience and it's a nice thing to be able to think about when you need something to kind of bring you back up. [00:24:12] Lindsey Dinneen: Yeah, absolutely. Just a different way of looking at the world from such a fun perspective. I love that. [00:24:19] Tyler O'Malley: Yeah. [00:24:20] Lindsey Dinneen: Yeah. Well, Tyler, this has been such a great conversation. I so appreciate your time today telling us a little bit about your story, the company, and all the incredible work that you guys are doing to change lives for a better world. And we are so honored to be making a donation on your behalf as a thank you for your time today to Save the Children, which works to end the cycle of poverty by ensuring communities have the resources to provide children with a healthy, educational, and safe environment. So thank you so much for choosing that charity to support, and thank you so much for being here and thank you for doing what you do. [00:24:59] Tyler O'Malley: Thank you. It's it's been a pleasure. [00:25:01] Lindsey Dinneen: Excellent, and thank you also to our listeners for tuning in, and if you're feeling as inspired as I am, I'd love it if you'd share this episode with a colleague or two and we'll catch you next time. [00:25:14] Dan Purvis:  The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world. 

At the Global Markets Forum hosted at OTC Markets Group's New York office, three leading exchange executives Jason Paltrowitz, Executive Vice President of OTC Markets Group; James Black, Vice President of the Canadian Securities Exchange; and Steve Henney, Co-Head of Business Development for the Aquis Stock Exchange joined Steve Darling from Proactive to discuss the evolving landscape of public market access and global investor engagement. Paltrowitz highlighted the OTC Markets' pivotal role as the largest U.S. stock market for non-U.S. equities, helping early-stage and international companies reach U.S. investors more efficiently. “We preach from the same hymnal,” he said, emphasizing the shared commitment between OTC Markets, CSE, and Aquis to make public markets more open, efficient, and accessible worldwide. Representing the CSE, Black spoke about the exchange's mission to support small and medium-sized enterprises seeking to raise public venture capital. He noted a strong synergy with OTC Markets, which helps CSE-listed issuers expand visibility and attract investment from U.S. capital markets. Henney provided the UK perspective, describing Aquis as a growth-focused exchange designed to give early-stage companies global exposure. He pointed to signs of recovery in both market activity and retail investor confidence, highlighting a robust IPO pipeline building over the next six months. The discussion also touched on improving market dynamics and increasing investor participation across regions. Black shared that the CSE is already $1 billion ahead of last year's performance, while Paltrowitz noted a significant uptick in trading volumes on the OTC particularly in the UK, Canada, and Germany as U.S. investors continue to look abroad for growth opportunities. All three leaders underscored the importance of long-term issuer support, consistent investor engagement, and cross-border collaboration to drive market strength. As Black concluded, “We have to provide optionality to our clients, it's not just happening in our own backyard.” #proactiveinvestors #otcmarkets #cse #aquisstockexchange #GlobalMarkets #PublicListings #InvestorAccess #SmallCapStocks #IPOMarket #StockMarketInsights #CapitalMarkets #MarketRecovery #USInvestors #InternationalListings #EquityMarkets #ProactiveInvestors

“Chemotherapy-induced alopecia does cause a lot of stress. It's associated with lower quality of life. Scalp cooling may really help improve quality of life. Some studies have shown that women in the scalp cooling group felt less upset about losing their hair and less dissatisfied with their appearance compared to the women in the control group that didn't receive any scalp cooling. So a lot of these studies are showing it does have a very positive impact on psychosocial feelings and side effects in relation to overall cancer treatment,” ONS member Jaclyn Andronico, MSN, CNS, OCN®, AOCNS®, clinical nurse specialist at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about chemotherapy-induced alopecia and scalp cooling. The advertising messages in this episode are paid for by Paxman. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ Episode 250: Cancer Symptom Management Basics: Dermatologic Complications ONS Voice articles: Diagnose and Manage Dermatologic Toxicity Secondary to Immunotherapy Follow the Evidence When Using Scalp Cooling for Cancer Alopecia Reimbursements Are Making Scalp Cooling More Accessible for Patients With Cancer The Case of the CIA-Combatting Combination ONS Voice oncology drug reference sheets: Docetaxel Doxorubicin Hydrochloride Sacituzumab Govitecan-Hziy ONS Guidelines™ for Cancer Treatment-Related Skin Toxicity Clinical Journal of Oncology Nursing articles: Chemotherapy-Induced Alopecia: Examining Patient Perceptions and Adherence to Home Haircare Recommendations Scalp Cooling: Implementing a Cold Cap Program at a Community Breast Health Center Scalp Cooling: Implementation of a Program at a Multisite Organization Oncology Nursing Forum articles: Effectiveness, Safety, and Tolerance of Scalp Cooling for Chemotherapy-Induced Alopecia The Effect of Chemotherapy-Induced Alopecia on Distress and Quality of Life in Male Patients With Cancer ONS Altered Body Image Huddle Card Journal of Market Access and Health Policy article: Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia HairToStay Paxman patient assistance program Rapunzel Project To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Some of the classes that are high risk for chemotherapy-induced alopecia can include antitumor antibiotics, such as doxorubicin, epirubicin; antimicrotubule drugs, such as taxanes like docetaxel, paclitaxel; alkylating agents such as cyclophosphamide. The lower risk alopecia-causing chemo agents are the antimetabolite classes, which a lot of people know as gemcitabine or fluorouracil. We also are seeing patients experience some degree of alopecia with a drug called sacituzumab govitecan, which is an actual antibody–drug conjugate.” TS 2:09 “Scalp cooling is approved for solid tumor patients. Patients receiving chemotherapy agents, as we discussed before, with that high incidence of chemotherapy-induced alopecia really should be considered for scalp cooling as long as they don't have certain contraindications. Some contraindications do exist for these populations. Those are patients that have cold agglutinin diseases, cryoglobulinemia, cryofibrinogenemia, and any cold sensitivity issues. Patients also with abnormal liver functions are not suggested to receive scalp cooling because their liver function is associated with the metabolism of the drug agent. It's also not recommended for patients with hematologic malignancies who are higher risk for cutaneous metastatic disease or failed chemotherapy and even reduced survival rates.” TS 9:23 “Overall, scalp cooling has a good tolerance, but it's important to be aware that scalp cooling can be uncomfortable for some, and it isn't always tolerated by some patients. Patients have reported side effects such as headaches, dizziness, chills, cold sensations, scalp pain, head discomfort, and even claustrophobia. Among these, the most common is the cold feeling and headaches. So when caring for patients that undergo scalp cooling, the nurses really should recognize the patient's feelings and help relieve that discomfort with position changes, prophylactic painkillers such as [acetaminophen] or [ibuprofen] if they're allowed to take that, additional warm blankets. Even antianxiety medications can really help, especially if that claustrophobia feeling is there. So collaborating with that team, the doctors, the nurse practitioners, just to be aware that if the patient's not comfortable during this treatment of scalp cooling, they should have those things on board prior to starting.” TS 12:23 “A lot of primary education points for nurses to review with patients is explaining the financial reimbursement process and assistance options—collaborating with that financial department within your institution. Also discussing the efficacy of the scalp cooling and the tolerability of it as well. I don't know if patients are always aware of the feeling of the cold—really warning them, letting them know what they're going to experience while in the chair attached to that cooling machine.” TS 18:55 “Nurses, we're at the forefront of scalp cooling, and we manage a lot of this area that comes with the service. They are managing, the coordination of the care, the education. They're assisting with that financial discussion and collaborating with the financial department. The symptom management—they're helping make the patients feel more comfortable with the symptoms of scalp cooling. They are the real deal here, so they are the best in helping with the situation. Nurses should be really familiar with the efficacy, again, and the tolerability, the contraindications, the side effects, and the costs and even the access for scalp cooling.” TS 20:57

In this episode, Puja Mehra speaks with economist Dr. Rajat Kathuria about the evolving landscape of India-US trade relations and the broader challenges of global economic engagement. Kathuria explains how India must balance political sensitivities in sectors like agriculture while ensuring competitive access to the US market. He highlights the importance of tariff reductions, strategic concessions, and diversification in trade and energy imports to attract investment and strengthen economic resilience. The discussion also delves into the role of media in shaping economic narratives and the lessons India can learn from China's measured rise. Kathuria emphasizes India's intrinsic entrepreneurial talent, frugal innovation, and the need to engage in global trade frameworks like CPTPP and RCEP. Tune in for insights on how India can leverage its strengths to become a leading global economic power.(00:00) Introduction(01:15) The Politics Behind India–US Trade Relations(04:40) Why Agriculture Is Always a Sticking Point(08:05) The Role of Tariffs and Market Access(11:20) What India Can Offer the United States(14:35) Mini Deals vs. Comprehensive Trade Agreements(17:10) How Global Trust Has Broken Down Since the Pandemic(20:25) India's Strategy for Building Economic Resilience(23:45) The Importance of Diversifying Energy and Trade Partners(26:30) Media Narratives and Policy Misunderstandings(29:10) Learning from China's Measured Global Strategy(31:45) Redefining India's Red Lines in Trade Negotiations(33:00) Why Rajat Kathuria Remains Optimistic About India's Future(34:56) ConclusionFor more of our coverage check out ⁠⁠⁠⁠⁠⁠⁠⁠thecore.in⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe to our Newsletter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow us on:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube

In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this episode unpacks what pharma companies need to know about preparing for an uncertain policy landscape through strategic scenario planning.Useful resources referenced in this episode:  You can download the article 'Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future' here. Details of the CELforPharma course 'Understanding Pharma Market Access in the US' are available on the CELforPharma website here. Send us a text

Dr. Jennifer Malinowski shares her role with Lab Corp and the work she does in Market Access. 

John Toomey covers diversification keys and how the practice has changed over time. He argues public markets have narrowed, with gains coming from a small share of companies, while private markets have ballooned. He discusses how private market access has expanded for 401(k) accounts and the opportunities for investors. John thinks the current system is “fundamentally wrong” by blocking retail investors out of private markets and thinks the discussion should be around “how do we do this in a responsible way?”======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

See omnystudio.com/listener for privacy information.

From U.S. Meat Export Federation The European Commission has proposed legislation that would allow some duty-free access for U.S. bison meat into the European Union. Under the legislation, the current 20% tariff on U.S. bison would be eliminated under an annual tariff rate quota (TRQ) for 3,000 mt of bison meat. National Bison Association Executive Director Jim Matheson says U.S. producers have long fought for equal access to the EU market. In a surprise announcement, Australia recently announced an end to restrictions on U.S. bison. Along with U.S. beef, U.S. bison had been effectively banned from Australia since the 2003 finding of bovine spongiform encephalopathy (BSE) in a dairy cow in Washington state. Matheson now sees positive signs for opening key Asian markets to U.S. bison, including Japan, South Korea and Taiwan.See omnystudio.com/listener for privacy information.

This episode is also available as a podcast, search "Global Viewpoint" on your preferred podcast player to watch, listen, and subscribe.Sheng Wang, Head of Banks and Institutional Client Group Scale Markets from HSBC sits down with Benton Wong, the Vice President, Head of Sales & Marketing from Bond Connect Company Limited, to discuss the development of Bond Connect since its 2017 launch. They'll cover how the program connects global investors to China's onshore bond market and latest initiatives relevant to China's market opening.Find out more here: https://www.business.hsbc.com/en-gb/campaigns/asia-credit-conferenceDisclaimer: Views of external guest speakers do not represent those of HSBC.

In this Almond Byte episode, the Almond Board of California's Global Trade and Regulatory Affairs (GTRA) team takes a look back at the 2024/25 crop year, highlighting progress on key trade and technical fronts. From securing a breakthrough aflatoxin pre-testing protocol for almond exports to Japan, to helping a 50% tariff reduction in Pakistan, ABC's efforts have expanded market access and strengthened global partnerships. The review also covers new initiatives in Morocco, Turkey, India, and beyond, as well as the recognition of almond quality standards at the UNECE forum and collaborative work with regulators to ensure the continued global movement of California almonds.

Tune in as Isabel and Jade analyse the standout moments from EMJ GOLD's guests this season, uncovering the challenges and opportunities shaping today's pharmaceutical industry. From self-advocacy at work and the future of personalised medicine to disease awareness, market access and making your marketing efforts stand out – they explore the season's core themes, all backed by the latest industry data. Watch our featured guest's full episodes: GSK's Dheepa Chari on the evolving sphere of scientific communication Yacin Marzouki on disrupting the traditional omnichannel model BMS' Anita Gandhi on a decade of change in hematology Pfizer's Richard Maughan on the future of access in the UK GSK's Matt Mortimer-Ryan on behaviour-led pharma marketing Chiesi's Shish Patel on COPD, the climate and improving care AbbVie's Dr Daejin Abidoye on community and compassion in cancer care Bayer's Dr Joana Reis on the promise of AI in breast cancer

On this episode of Alternative Power Plays, Buchanan's Alan Seltzer and John Povilaitis welcome Jon Gordon, Director at Advanced Energy United. Advanced Energy United (AEU) is an industry association and advocacy group that represents the full range of advanced energy technologiesand services, both grid-scale and distributed. In his role, Jon leads AEU's work to increase wholesale electricity market access for advanced energy technologies, including related transmission expansion.The conversation centers around PJM, the regional transmission organization (RTO) that coordinates the movement of wholesale electricity in 13 states and Washington, D.C. In February, AEU published a report examining the results of PJM's capacity auction for 2025-2026, which saw prices surge to $14.7 billion, an increase of $12.5 billion from the previous auction. The three discuss the results of that report and how it will impact customers, what's driving high prices, what additional reforms and remediation are needed to improve interconnection, and more.On a previous episode of Alternative Power Plays, Seltzer and Povilaitis sat down with Gordon's colleague, Ryan Gallentine, Managing Director of Advanced Energy United where they discussed what policies Gallentine is focused on to help move electric vehicle adoption forward. To hear that conversation, visit: https://share.transistor.fm/s/f8e6940d. To learn more about Advanced Energy United, visit: https://advancedenergyunited.org/  To learn more about Jon Gordon, visit: https://advancedenergyunited.org/about/team/jon-gordonTo learn more about Alan Seltzer, visit: https://www.bipc.com/alan-seltzer To learn more about John Povilaitis, visit: ⁠https://www.bipc.com/john-povilaitis

AOTI Inc. CEO Dr. Mike Griffiths joined Steve Darling from Proactive to announce a key milestone in the company's commercial expansion strategy: the successful approval of a new Provider ID in California. This designation allows AOTI to begin securing insurance coverage and reimbursement for its patented TWO2® Topical Wound Oxygen therapy in the country's most populous Medicaid market, paving the way for broader growth in late 2026. California represents a major strategic opportunity, with 14.7 million individuals—or 38% of the population—covered under Medi-Cal, the state's Medicaid program. The addition of California marks the third state in 2025 where AOTI has secured provider status, aligning with the company's guidance of adding two to three states annually as part of its U.S. expansion. Griffiths emphasized that the TWO2® therapy, which is non-invasive and self-administered at home, has been clinically proven to significantly reduce the recurrence of Diabetic Foot Ulcers. Robust randomized controlled trials and real-world evidence have shown an 88% reduction in hospitalizations and a 71% reduction in amputations over 12 months—outcomes that not only improve quality of life but reduce healthcare system burden. Financially, AOTI reported 26% revenue growth in the first three months of the period and 37% growth for the six months ended March 31, 2025—driven by strong post-IPO momentum. Despite these short-term headwinds, AOTI remains confident in its long-term growth trajectory, forecasting mid-teens revenue growth and low double-digit adjusted EBITDA margins for FY 2025. The company views current macroeconomic challenges as transitional and reaffirmed its commitment to executing its strategic plan and expanding market access for its differentiated wound care technology. #proactiveinvestors #aotiinc #aim #aoti #DiabeticFootUlcers #WoundCare #OxygenTherapy #HealthcareInnovation #Medicaid #VeteransHealth #CaliforniaHealthcare #ProactiveInvestors

Today, we're looking at Crown prosecutors seeking seven- or eight-year jail terms Freedom Convoy organizers Tamara Lich and Chris Barber following the longest mischief trial in Canadian history. Plus, in sharp contrast to the stiff sentence facing the protesters, a 14-year-old boy in Toronto has been detained in custody following the unprovoked killing of a 71-year-old woman. And finally, as part of trade negotiations, the U.S. is seeking full access to Canada's market. Could supply management and the dairy cartel finally be dismantled as part of a new trade deal?

In this episode of Unearthed, co-hosts Joe Cavatoni and John Reade, Senior Market Strategists for the World Gold Council, are joined by Amanda Krichman, Chief Operating Officer of Funds at the World Gold Council. Together, they unpack the fundamentals of gold-backed ETFs, taking a closer look at how these products work and address some of the most common myths in the market. The conversation covers everything from how gold ETFs are created and redeemed to the role of authorised participants (APs) in maintaining price stability and liquidity. Together, they also reflect on 20 years since the launch of GLD, the first U.S.-listed gold ETF, and explore how ETFs have revolutionised access to gold for both retail and institutional investors. Notable Quotes:  “An ETF, or as it's known, an exchange-traded fund, pools assets from many different investors and gives them an easy option to buy into a diversified product. They'll buy shares of this product, which will allow them to get access to many different underlying investments.” — Amanda Krichman   “I've seen it with my own eyes. For the two products that we work on with GLD and GLDM, the gold is there. The shares of the fund won't be released until the physical gold bars are delivered and allocated within the accounts for each of the ETFs.” — Amanda Krichman  “You might be wondering, how do these authorised participants make money? It's based on the arbitrage of how that's trading in the secondary market and to help keep the price as close as possible, less expensive to the underlying value of the gold per share.”  — Amanda Krichman  Disclaimer:  For additional information on SPDR® Gold Shares (GLD®) and SPDR® Gold MiniShares (GLDM®), please visit www.spdrgoldshares.com.   The information is for educational purposes only and is not intended to constitute a recommendation, investment advice, or offer for the purchase or sale of gold, any gold-related products or services or any other products, services, securities or financial instruments. Investing involves risk, including any investment in GLD or GLDM.  Before making any investment, you should read GLD's prospectus which is available here and GLDM's prospectus which is available here and consult your tax and financial advisor. Additional Resources www.gold.org  Amanda Krichman LinkedIn About World Gold Council We are a membership organisation that champions the role gold plays as a strategic asset, shaping the future of a responsible and accessible gold supply chain. Our team of experts builds understanding of the use case and possibilities of gold through trusted research, analysis, commentary, and insights. We drive industry progress, shaping policy and setting the standards for a perpetual and sustainable gold market. You can follow the World Gold Council on X at @goldcouncil and LinkedIn. Terms & Conditions | World Gold Council Correction notice: Please note a small error in this recording. At 3mins 47sec Amanda notes that the custodian releases the shares once the gold is delivered to the custodian. However, technically it's the admin that releases the shares once the gold is delivered to the custodian.

Dena Jalbert reacts to Ferrero buying WK Kellogg (KLG) at $23/share, a 40% premium. Part of the premium, she argues, is because the deal lets Ferrero enter the U.S. breakfast market – and another part is KLG's existing debt. She thinks this was a “specific and intentional” deal and doesn't think KLG is looking for other merger offers. She talks about global consumer tastes and Kellogg's healthy options in addition to the sugary. Dena also discusses pricing power for consumer staples companies.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-...Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-...Watch on Sling - https://watch.sling.com/1/asset/19192...Watch on Vizio - https://www.vizio.com/en/watchfreeplu...Watch on DistroTV - https://www.distro.tv/live/schwab-net...Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

Farm Bureau analysis shows U.S. ag imports outpacing exports at historic levels as global competition and trade barriers mount.

This session was recorded on Thursday, 12th June, at the AviaDev Africa event in Zanzibar. Key topics include ownership models, market access barriers, regulatory challenges, and strategies to unlock capital and promote growth in the sector. Panelists share their perspectives on the significance of liberalizing the air transport market through initiatives like SAATM, the importance of risk management, and the critical need for investments in local talent and infrastructure. Despite diverse views, there is a consensus on the necessity for enhanced regulatory reforms and regional cooperation to foster a more competitive and thriving aviation industry in Africa.  Your moderator for this session is Hilka Birns and she was joined by: Helen Brume, Director, Projects & Asset Based Finance, Afreximbank Munawer Dhirani, CEO, Flightlink Julian Edmunds, Group Strategy & Development Director, Fastjet Mesfin Tasew, Group Chief Executive Officer, Ethiopian Airlines Peter Ulanga, Managing Director & CEO, Air Tanzania

In this episode of The Kula Ring, Sam Rajkovich dives into the complexities of working with independent manufacturers' representatives. He unpacks how to compete for reps' time and attention, maintain brand consistency across third-party sellers, and build emotional connections that create loyalty. Sam also explores the economic tradeoffs of the model, its scalability, and its uncertain future as younger professionals shy away from commission-only roles. From messaging challenges to hybrid sales strategies, this episode offers a candid look at the evolving landscape of indirect sales in manufacturing.

Stephen Grootes speaks to Zihaad Israfil, CEO of CFI South Africa, about how digital platforms are empowering younger investors with direct market access and educational tools. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Many MedTech companies focus heavily on FDA clearance but overlook a critical layer of U.S. market entry: state-level compliance. In this episode, Etienne Nichols speaks with Adam Steadman, CEO of MDD Options, to unpack the real-world challenges that derail commercialization after regulatory approval. From navigating state-specific registration, sales tax laws, and distribution logistics to choosing between direct and distributor-based strategies, Adam shares hard-earned insights for avoiding the "second valley of death" post-clearance. Whether you're a domestic startup or an international company entering the U.S., this episode arms you with a tactical understanding of compliance landmines and scalable go-to-market strategies.Key Timestamps00:02 – Intro: The real MedTech “valley of death” after FDA clearance04:45 – Why U.S. state-level registration is misunderstood and overlooked08:15 – State-level definitions of medical devices and why they differ11:20 – Strategic go-to-market options: Distribution vs. Direct17:00 – How regulations vary drastically by state (CA, TX, etc.)21:50 – The real risks of noncompliance: lawsuits, bad PR, and due diligence failures26:15 – Why distribution agreements can stall your growth (and how to avoid it)34:30 – Sales tax & use tax: The hidden compliance trap39:10 – Logistics, warehousing, and long-term liabilities in contracts44:55 – Overlooked pitfalls: Secretary of State filings and income tax in 36+ states51:15 – Software as a Medical Device (SaMD): U.S. compliance still applies55:30 – Selling to the U.S. government vs. private sector buyers59:20 – Veterinary devices and why they still need regulatory controls1:03:10 – What a winning go-to-market strategy actually looks like1:10:25 – Adam's final advice to MedTech startups (foreign and domestic)Standout Quotes"You're not entering one country—you're entering 50 states and D.C. Each with its own rules, definitions, and tax laws."—Adam Steadman explains why U.S. MedTech entry requires a state-by-state strategy, especially for international companies."None of the strategics want your warehouse management system—they want your product, your sales, and your proof of market fit."—Steadman on why building non-core infrastructure slows down commercialization and valuation.Top 5 TakeawaysFDA Clearance ≠ Market Readiness – State-level registrations, sales tax laws, and pharmacy board definitions often delay or block commercialization.Distribution Isn't Always a Shortcut – National distributors may have misaligned incentives and can lock you into exclusivity that hinders growth.Sales Tax is a Regulatory Minefield – 46 states require separate sales tax registration, exemptions tracking, and monthly filings—even if you're tax-exempt.Beware of Long-Term Contracts – Logistics and distribution contracts often lock companies into rigid terms that prevent pivots or acquisitions.Speed to Market Is Strategic – Getting to market fast is often the difference between becoming #1 or #3—and #3 often gets nothing.MedTech 101What Is “Nexus” and Why It Matters for Sales Tax?“Nexus” refers to the minimum level of economic activity that triggers tax obligations in a given state. For example, selling $100,000 of devices or 200 transactions may establish nexus, requiring you to register for sales tax. Unlike VAT in Europe, U.S. sales tax laws are state-specific, making this a major compliance hurdle for MedTech companies.References & Resources

Julio G. Martinez-Clark CEO of Bioaccess and President of IAOCR/GCSA Americas is a MedTech trailblazer helping startups accelerate First-in-Human (FIH) clinical trials across Latin America, with over 20 years of experience spanning healthcare, telecom and venture capitalIn this episode, we unpack why more MedTech companies are turning to LATAM for faster, more cost-effective trial execution. Julio shares how his Miami-based CRO helps deliver 58-day CE mark approvals, his experience supporting 100+ device startups and why time, not money, is the most precious currency for early-stage founders. We also touch on trial quality, regulatory strategy and why he believes Latin America will play a defining role in the next era of global MedTech innovationTimestamps:[00:00:47] Why LATAM Is the Next MedTech Trial Hub[00:02:21] The Problem with FIH Trials in the U.S.[00:04:42] How bioaccess® Reduces Approval Timelines by 70%[00:06:01] Strategic Sites, Patient Retention & CRO Infrastructure[00:08:17] Do LATAM Trials Hold Up to FDA & EU Scrutiny?[00:10:43] The Fundraising Pressure Behind Faster Clinical Results[00:12:22] Founder Mistakes in In-House Trial Management[00:14:11] Why LATAM May Overtake Eastern Europe in FIH Volume[00:17:26] Regulatory Standards, UNESCO, and Regional Quality[00:20:10] Julio Outside the Office: Family, Fitness & PodcastingGet in touch with Julio - https://www.linkedin.com/in/juliomartinezclark/Learn more about Bioaccess - https://www.bioaccessla.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

In this special edition of The Distribution, host Brandon Sedloff sits down with Chris Tinsley and Rory Mabin of NASDAQ's fund secondaries business, recorded live from NASDAQ's Times Square studio.  The conversation unpacks the evolution of the fund secondaries market, highlighting how NASDAQ is bringing technology, transparency, and regulatory clarity to a historically opaque and manual process. Chris and Rory share how their unique professional journeys—from institutional investing to pioneering fintech—positioned them to rethink secondary liquidity in private markets.  They dive deep into the complexities of LP transactions, the origins of NASDAQ's platform, and the structural and regulatory innovations making scaled, GP-sponsored liquidity a reality today. They discuss: * How NASDAQ's acquisition of SecondMarket evolved into a fund secondaries platform * Why secondary LP transactions are more like M&A deals than stock trades * The value of “GP-sponsored” liquidity programs and how they differ from GP-led deals * How NASDAQ's Qualified Matching Service (QMS) helps GPs avoid tax complications while scaling liquidity * Why scalable technology and a growing buyer base—including family offices and institutional LPs—are reshaping the future of private market secondaries This episode is essential listening for GPs navigating LP liquidity needs or building next-gen fund structures in private markets. Links: Nasdaq Fund Secondaries - https://www.nasdaq.com/solutions/fund-secondaries Chris Tinsley on LinkedIn - https://www.linkedin.com/in/christoffertinsley/ Rory Mabin on LinkedIn - https://www.linkedin.com/in/rory-mabin-966a1333/ Brandon on LinkedIn - https://www.linkedin.com/in/bsedloff/ Juniper Square - https://www.junipersquare.com/ Topics: (00:00:00) - Intro (00:01:20) - Introducing Chris Tinsley and Rory Mabin (00:01:45) - NASDAQ's role in private market secondaries (00:02:09) - Chris Tinsley's journey to NASDAQ (00:03:55) - Rory Mabin's background in fund secondaries (00:05:04) - Understanding NASDAQ beyond the exchange (00:06:40) - The origin of NASDAQ's fund secondaries business (00:10:28) - Challenges in fund secondaries transactions (00:17:40) - The role of technology in streamlining processes (00:23:49) - Adapting to investor needs in private markets (00:27:26) - Enhanced liquidity options for limited partnerships (00:31:02) - Understanding Qualified Matching Service (QMS) (00:33:28) - Challenges and solutions in providing liquidity (00:36:52) - The role of technology in liquidity solutions (00:38:03) - Practical implementation of embedded liquidity (00:46:37) - The future of secondary markets and AI integration (00:50:02) - Conclusion and final thoughts

In this special edition of the Syneos Health Podcast recorded from the floor of Asembia's AXS25 Summit, host Michael Sarshad sits down with Kim Plesnarski, SVP of Market Access and Patient Support Services at Syneos Health and Kelly Carter, AVP of Patient Support at Amgen, to unpack the evolving landscape of patient support. The discussion explores the blurring lines between general and specialty medicine, the growing administrative burden on providers and the need to embed seamless, tech-enabled support into the healthcare journey. The trio dives into the role of Field Reimbursement Managers (FRMs), payer challenges, affordability barriers and how AI and automation are beginning to transform operations—from personalized patient education to proactive intervention. If you're interested in how manufacturers can shift from reactive to proactive models and scale personalized support in an increasingly complex environment, this episode is a must-listen.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode of our Navigating Modern Market Access series, recorded from the floor of Asembia's AXS25 Summit, host Sara Rubin sits down with Rob Truckenmiller, the newly appointed CEO of PharmaCord. Drawing from his deep experience across small, mid-sized and large pharmaceutical companies, Rob explores how market access strategies must evolve to meet today's healthcare challenges. From the integration of patient services and payer strategies to the role of technology and data in shaping outcomes, Rob shares his perspective on how pharma companies can empower patients, optimize gross-to-net and navigate the complex US healthcare landscape. Tune in for actionable insights on building a smarter, more patient-centric access model.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this special edition of the Syneos Health Podcast recorded from the floor of Asembia's AXS25 Summit, host Michael Sarshad speaks with Kim Plesnarski, SVP of Market Access and Patient Support Services at Syneos Health and Greg Morris, Chief Strategy Officer at CareMetx. They explore the latest trends shaping patient support services—from the surge of AI-powered solutions to the shift toward hybrid hub models. The conversation dives into the challenges of reactive support programs, the need for continual innovation and the nuanced debate between insourcing and outsourcing. With practical insights and real-world examples, Kim and Greg share strategies for building scalable, tech-forward patient service models that meet the evolving demands of both patients and providers.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals, a company that has been serving as a regional affiliate for pharma and biotech since 1981 in the CEE and Mediterranean. Market access strategies in many international markets do not function the same way as they do in the US or Western Europe and require a different approach. Zorlular explains how EAPs can drive revenue for pharmaceutical companies from international unlicensed markets, but that most importantly EAPs allow patients access to life-altering novel medicines. What's more, he says, EAPs can also help shape the biotech space by supporting the opportunity for RWD collection outside of the clinical trial setting and build momentum with local payers, regulators, and the medical community. You can listen to episode 179a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

A Future of Finance interview with Milo Guastamacchia, Founder and CEO or Yooro.Technology-driven securitisation platform Yooro aims to simplify investor access to private markets, focusing on investors in the European Union, UK, Switzerland and the UAE. The company's Founder and Chief Executive Milo Guastamacchia speaks to Bob Currie about how this is reshaping approaches to fundraising in unlisted markets, while attracting new and wider categories of investor that may not have been attracted previously to private capital issues or structured products.The result, says Guastamacchia, is a more “democratic” pathway for private markets investment, delivering better access to the market, greater transparency and improved ‘voice' for the investor.The sweet spot for Yooro is to apply securitisation and tokenisation in tandem, bringing real-world assets into a digital DLT-based environment and building secondary market liquidity in those instruments. Assets are typically held by a special purpose vehicle wrapper under Luxembourg law.More broadly, the discussion reflects on Yooro's formation and ambitions, delivery of its Securitisation-as-a-Service methodology, and what the future holds as it expands its product set and solutions coverage. Hosted on Acast. See acast.com/privacy for more information.

This is Zack Fuss. Today, we are breaking down Interactive Brokers, widely recognized as IBKR. Founded in 1978, Interactive Brokers evolved from a market maker on the American Stock Exchange to a global, cutting-edge electronic brokerage firm. Its founder, Thomas Peterffy, remains far and away its largest shareholder and has earned his place as one of the wealthiest people in the world. To break down IBKR, I'm joined by Freddie Lait and Jacopo Di Nardo of Latitude Investment Management. We explore the journey of IBKR from its early days as Timber Hill to its current status as a publicly traded company with a market cap of nearly $80 billion. We also discuss their differentiated tech stack, their global reach, and their famously low fees. Please enjoy this breakdown of Interactive Brokers. Subscribe to Colossus Review For the full show notes, transcript, and links to the best content to learn more, check out the episode page here. —- This episode is brought to you by Octus, formerly Reorg, is the essential credit intelligence and data provider for nearly 40,000 professionals across the world's leading buy side firms, investment banks, law firms and advisory firms. By surrounding unparalleled human expertise with embedded AI technology, data and workflow tools, Octus unlocks powerful truths that fuel decisive action in financial markets. Visit octus.com to learn how rigorously verified intelligence is delivered at speed to create a complete picture across the entire credit lifecycle.  —- Business Breakdowns is a property of Colossus, LLC. For more episodes of Business Breakdowns, visit joincolossus.com/episodes. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Show Notes (00:00:00) Welcome to Business Breakdowns (00:03:41) Overview of Interactive Brokers (00:04:53) Revenue Streams and Business Model (00:06:15) Competitive Landscape and Differentiation (00:08:38) Founder Thomas Peterffy's Story (00:11:31) Payment for Order Flow and Market Access (00:13:41) Automation and Risk Management (00:16:50) Customer Experience and Balance Sheet Strategy (00:26:33) Growth Opportunities and International Expansion (00:34:34) Valuation and Financial Metrics (00:37:28) Risks and Stress Tests (00:42:13) Lessons From IBKR

After losing both her sister and a close friend to cancer in the same year, Carissa Rollins knew she couldn't stay where she was. As CIO of UnitedHealthcare, she had scale and power, but not proximity to the technology that might have changed those outcomes. So when the call came from Illumina, a company pioneering genomic sequencing, she listened. And then she leapt. In this episode of Inspiring Women with Laurie McGraw, Carissa shares how grief reshaped her career and how purpose—not title—has always been her compass. She talks candidly about what it means to walk away from the “biggest job of your life” to chase deeper impact, and how she's now using her insider knowledge of the payer system to open doors for patients who would otherwise be left out of the genomic revolution. Carissa also reflects on the turning points that built her leadership style—from writing a three-page letter to fight for a promotion, to insisting on coaching even when her boss said she didn't need it. She's quick to credit the mentors who pulled her forward—but equally passionate about pulling others up behind her. “Why are you sitting in the back?” she recalls asking one young woman. “Your voice is important.” Now at Illumina, she's helping her teams think critically about how AI can reduce burnout—not by cutting jobs, but by removing outdated, burdensome processes and freeing people to do more meaningful work. It's a nuanced, systems-based view that resists the hype and centers on impact. You'll also hear Carissa speak on: Why she sees restlessness as a sign it's time to grow The alarming drop in women in tech—and what we can do about it How the Grand Canyon Conservancy helps her stay grounded (and where she thinks tech could help the parks) What it really takes to make space at the table—and why women can't afford to close the door behind them This conversation is full of hard-earned wisdom, honest reflections, and a fierce belief in using every ounce of power to move others forward. Chapters 03:52 Overcoming Restlessness & Seeking New Challenges 10:05 Impact, Market Access & Personal Fulfillment 14:59 AI's Role in Operations & Efficiency 15:53 Inspiring Young Women in Technology 17:38 Challenges & Setbacks for Women in Tech 19:52 Empowering Advice for Future Leaders Guest & Host Links Connect with Laurie McGraw on LinkedIn Connect with Carissa Rollins on LinkedIn About Illumina Connect with Inspiring Women Browse Episodes | LinkedIn | Instagram | Apple | Spotify This episode of Inspiring Women with Laurie McGraw was recorded at the WBL Summit, a leadership, networking, and professional development conference for WBL members that takes place each spring. WBL is a network of 1500+ senior executive women in healthcare who convene to share ideas, make valuable connections, and solve business challenges. WBL's mission is to connect and support our members in advancing their careers and impact on our industry.

Graeme Raubenheimer is in conversation with Abrie Rautenbach - Head of Absa AgriBusiness, about the immediate future of South Africa’s citrus industry – this on the back of impending tariffs from the US, but a growing demand elsewhere in the world. Afternoon Drive with John Maytham is the late afternoon show on CapeTalk. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30 pm. CapeTalk fans call in, in an attempt to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live – Afternoon Drive with John Maytham is broadcast weekdays between 15:00 and 18:00 (SA Time) https://www.primediaplus.com/station/capetalk Find all the catch-up podcasts here https://www.primediaplus.com/capetalk/afternoon-drive-with-john-maytham/audio-podcasts/afternoon-drive-with-john-maytham/ Subscribe to the CapeTalk daily and weekly newsletters https://www.primediaplus.com/competitions/newsletter-subscription/ Follow us on social media: CapeTalk on Facebook: www.facebook.com/CapeTalk   CapeTalk on TikTok: www.tiktok.com/@capetalk   CapeTalk on Instagram: www.instagram.com/capetalkza  CapeTalk on X: www.x.com/CapeTalk  CapeTalk on YouTube: www.youtube.com/@CapeTalk567  See omnystudio.com/listener for privacy information.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he breaks down today's biggest stories shaping America and the world. Trump's First 100 Days: Achievements and Challenges – President Trump celebrates 100 days in office with mixed polling results. While Democrats move to impeach him, fresh data shows Trump is still preferred over Democrats on key issues like immigration and national security. Meanwhile, the U.S. economy shows resilience despite tariff pressures, though supply chain concerns loom. Border Security Milestone: Near Total Control Achieved – Only nine migrants have been released into the U.S. during Trump's term so far, compared to 9,000 daily under Biden. The administration is also building a massive new database to target millions of illegal immigrants for deportation. Houthis Use Chinese Intel to Strike U.S. Navy – A Chinese satellite company supplied intelligence that helped the Houthis target the USS Harry Truman in the Red Sea, leading to the loss of a $60 million Navy jet. Bryan calls for a tougher U.S. response to China's proxy aggression. Spain's Massive Blackout Raises Cyberattack Fears – Spain suffers a nationwide power outage, prompting concerns about Russian cyberattacks and vulnerabilities tied to green energy dependence. Bryan warns listeners to prepare for disruptions. China's Sneaky Plan to Evade Trump Tariffs – Chinese companies are working through Indian intermediaries to bypass U.S. tariffs, highlighting both the resilience of global markets and the need for a more effective American reshoring strategy. Bryan proposes offering Indian companies incentives to establish factories in the US instead. Get the facts, the analysis, and the truth - only on The Wright Report. "And you shall know the truth, and the truth shall make you free." - John 8:32​

The biopharma market is booming—but not without turbulence. In this kickoff episode of our special podcast series in collaboration with Asembia, hosts Michael Sarshad, Managing Director, Commercial Advisory, Syneos Health and Sara Rubin, Senior Vice President, Market Access Strategy at Spherico, a Syneos Health company, unpack the dynamic forces reshaping how therapies reach patients. Recorded ahead of Asembia's AXS25 Specialty Pharmacy Summit, they dive into the impact of tariffs, the power of AI in streamlining patient support, the ripple effects of the Inflation Reduction Act and how digital transformation is changing the way manufacturers engage population health decision-makers. Tune in for expert insights, preview topics for this year's summit, and discover how the industry is responding to rising complexity with strategic innovation.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Chip Moebus, VP Market Access, joined the Chase MedSearch Podcast to discuss the difficulties of getting accurate data for epileptic patients on the type of epileptic seizure they've suffered and the frequency rate. He further discussed how the Minder System has the potential to provide extraordinarily insightful data that Neurologists have never been able to capture before.    www.epiminder.com

In this episode, host Mitch Robbins interviews Mickey Brown, Vice President of Access and Reimbursement at Cerapedics, discussing his 30+ year career journey and insights on healthcare market access.Key Highlights:Mickey shares his transition from 15 years on the payer side (Blue Cross, United Healthcare) to manufacturer roles at Medtronic, Cochlear, and now CerapedicsLearn how stepping outside his comfort zone at critical moments propelled his career forwardDiscover the biggest challenges facing market access professionals in 2025Understand common reimbursement strategy mistakes companies make and how to avoid themPractical Takeaways:Why waiting too long to develop reimbursement strategy hurts product launchesThe key differences between director and VP-level thinkingWhat makes an outstanding market access professionalHow to effectively engage with increasingly inaccessible payersWhether you're in medical device sales, reimbursement, or aspiring to leadership roles in healthcare, this conversation offers valuable insights from both sides of the healthcare ecosystem.

Chinese Premier Li Qiang has reiterated the country's commitment to openness and global collaboration, saying China will further expand market access for foreign investors.

In this episode, I welcome back Necdet Gunsoy, who's now in a new role as the founder of EviMed, a boutique consultancy specializing in health economics, outcomes research, real-world evidence, and market access. We dive into the often tense relationship between statisticians and market access professionals, exploring why these functions struggle to collaborate and, more importantly, how we can work together more effectively.

Manuel Nordeste is Vice-President at Fidelity Digital Assets and leads the business development team outside of the United States.In this episode, Manuel discusses the evolving landscape of Bitcoin and digital assets, focusing on market sentiment, institutional interest, and the role of Fidelity Digital Assets. Exploring how regulatory changes and educational efforts have influenced corporate strategies and investor behaviour, particularly in relation to ETFs and the impact of companies like MicroStrategy. The episode was recorded on the 28th of Feb, 2025.Fidelity Digital Assets:- Bitcoin First (original): https://fwc.widen.net/s/kx6vn9hkfw/bitcoin-first- Bitcoin First (updated): https://fwc.widen.net/s/vbgwdtmnrf/1012662.6.0---fdas-bitcoin-first-revisited-v1- 2025 Look Ahead: https://fwc.widen.net/s/zrvf5hfjfs/fda-2025-look-ahead-report---final- Manuel Nordeste: https://www.linkedin.com/in/mnordeste/----Jordan's Bitcoin Products and Event Links:

Have you ever wondered why so many new drugs fail even after years of research and billions in investment? In this episode, we dive deep into the challenges of drug commercialization, the role of AI in pharma, and the biggest mistakes companies make before going to market.Our guest, Dan Cummings, is a leading expert in go-to-market strategy, having worked with top health tech, medtech, and biotech startups. He shares insider insights on why even successful clinical trials don't guarantee a product's success and how companies can improve their chances.We also explore:- The shocking statistics behind drug approvals - Why less than a third of new drugs in 2025 will meet expectations- The #1 mistake pharma companies make before launch - How AI is transforming drug development & commercialization - What makes some drugs cost millions of dollars, while others are much cheaper This episode is packed with industry insights, expert opinions, and bold predictions about the future of pharmaceuticals.Chapters:00:00 Introduction03:54 The Challenges of Drug Commercialization05:35 Market Access & Value-Based Pricing12:00 Predictions for 2025 Drug Approvals13:23 The Role of AI in Pharma16:59 Why Most Drug Launches Miss Expectations18:25 Lessons from Biotech Success Stories23:46 The Future of Pharma & Go-to-Market Strategies29:31 How Companies Can Improve Their Launch Success35:56 Final Thoughts & Takeaways

This week, our guest is Anne Applebaum, a Pulitzer Prize-winning journalist, historian, and New York Times bestselling author. Her latest book, Autocracy Inc.: The Dictators Who Want to Run the World, explores the global rise of authoritarianism.On February 6th, 2025, Anne spoke at the University of Calgary's Haskayne School of Business annual PETRONAS International Energy Speaker Series. This episode was recorded live at the event.Jackie Forrest moderated the discussion with Anne Applebaum, which covered a wide range of topics, including the timing of her new book, the Trump administration's early actions and executive orders, and the recent deterioration of Canadian-US relations.Please review our disclaimer at: https://www.arcenergyinstitute.com/disclaimer/ Check us out on social media: X (Twitter): @arcenergyinstLinkedIn: @ARC Energy Research Institute Subscribe to ARC Energy Ideas PodcastApple PodcastsAmazon MusicSpotify 

Join Isabel and Jade for part two of their World Cancer Day special for 2025, where guest Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, Johnson & Johnson, uncovers more of his insights into the oncology space.  In this instalment, Martin shares his thoughts on improving access to innovative cancer medicines, improving public trust toward the industry and his personal leadership style.  A little more on GOLD's guest… Martin Price is Vice President for Health Economics, Market Access and Reimbursement in Europe, the Middle East and Africa, Johnson & Johnson, a role he has held for the past eight years. He leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Johnson & Johnson's new products and indications. Prior to this, Price worked in Johnson & Johnson's UK affiliate, latterly as director of external affairs, where he was responsible for market access, communications and government affairs. He joined Johnson & Johnson in 2001 from GlaxoSmithKline, where he began his career as senior health-outcomes manager. 

The opening of Mexico to fresh table stock exports has created significant benefits for U.S. producers, Mexican consumers and even Mexican growers as demand for potatoes increases. During Potato Expo 2025, we brought together four industry experts to provide valuable insights on the challenges and opportunities surrounding U.S. potato exports. The episode highlights the 25-year journey to open the Mexican market for U.S. potatoes, demonstrating the collaboration between industry leaders and government officials. • Overview of the 25-year effort to gain market access • Strategies by Potatoes USA to educate Mexican consumers • Differences in consumer preferences and purchasing power analysis • Challenges in distribution channels and traditional market dynamics • Importance of consumer sampling and education in driving demand • Ongoing phytosanitary concerns and mitigation strategies • Outlook on growth potential and market share for US potatoes in MexicoGuests:Kim Breshears, Chief Marketing Officer, Potatoes USAKam Quarles, CEO, National Potato CouncilLuis Moreno, CEO, Grupo PMMatt Lantz, Senior Vice President of Global Access, Bryant Christie Inc.This podcast is possible thanks to our presenting sponsor, Syngenta. Delivering solutions to help producers face the potato industry's complex challenges, Syngenta provides growers with unmatched field expertise along with an array of effective products. Explore syngenta-us.com/spud-doctor to discover solutions for your potato-growing obstacles. 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Dean McAlister, Executive Vice President at Inizio Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dean, covering: The evolving dynamics within the life sciences sector and how they are shaping outsourcing strategies Key insights and trends from J.P. Morgan week, including challenges and opportunities for CROs and CDMOs The Impact of cautious optimism on Business Development teams and commercial strategy in the current market Climate Why 2025 may be a year of incremental growth and how contract service providers can position themselves for success amidst swirling market headwinds The importance of strategic customer engagement and brand positioning for smaller, specialized players to gain an edge over global CDMO giants Dean brings a wealth of experience from his leadership role at Inizio Biotech, where he focuses on driving growth, innovation, and operational excellence. Prior to joining Inizio, he held executive leadership roles at AstraZeneca in US Commercial Sales and Market Access, leading teams of up to 1,100 people and overseeing high-impact strategies in a highly competitive environment.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

The Chinese Commerce Ministry says it will boost opening-up and ease market access this year. Officials say the country will steadily advance the opening-up of the service industry after lifting all foreign investment restrictions in the manufacturing sector.

In this episode of the NASP Podcast, Sheila Arquette, President & CEO of NASP, speaks with Bridgette Kanz Schroader, PharmD, MPA, BCOP, Associate Director within the Medical Affairs Strategy & Publications team at Market Access & Healthcare Consulting, part of Cencora, and Laurie Fayzio, Head, Manufacturer Strategy, at FormularyDecisions. They explore the changing landscape of digital communication between biopharma companies and healthcare decision makers (HCDMs) and delve into 3 key topics that are crucial for effective engagement in the digital era with key decision makers: research on how HCDMs are utilizing digital resources and valuable insights into their preferences, how biopharma companies are adapting to meet the evolving needs of HCDMs in a post-pandemic peak era, and innovative strategies to optimize digital communications and the implications for stakeholder relationships.

Episode 44 - Shay Speakman-Brown, Head of Market Access for Dexcom UK and Ireland, brings extensive experience in healthcare, excelling in business strategies, market expansion, and managing multi-franchise projects. Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only.  The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees.  We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.

We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's (Gates MRI) Dr. Claire Wagner joins us to share insights into her work as head of Corporate Strategy and Market Access there. She shares the development of her North Star while working with the incomparable Dr. Paul Farmer in Rwanda, and how that experience translates to the growth of a biopharmaceutical company taking big swings for grossly underserved populations. We discuss the nuances assoiated with setting strategy and enabling product access in a unique not-for-profit setting, and how, perhaps counterintutively, the Institute's work fits synergistically into an ultra-competitive for-profit biopharma landscape. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.comFind Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/